ATE309383T1 - Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe - Google Patents

Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe

Info

Publication number
ATE309383T1
ATE309383T1 AT97919307T AT97919307T ATE309383T1 AT E309383 T1 ATE309383 T1 AT E309383T1 AT 97919307 T AT97919307 T AT 97919307T AT 97919307 T AT97919307 T AT 97919307T AT E309383 T1 ATE309383 T1 AT E309383T1
Authority
AT
Austria
Prior art keywords
predrug
activation
cells expressing
encapsulated cells
cytochrome
Prior art date
Application number
AT97919307T
Other languages
English (en)
Inventor
Walter H Guenzburg
Peter Karle
Robert Michael Saller
Original Assignee
Bavarian Nordic As
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309383(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE309383T1 publication Critical patent/ATE309383T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AT97919307T 1996-03-27 1997-03-27 Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe ATE309383T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK35296 1996-03-27
PCT/EP1997/001585 WO1997035994A2 (en) 1996-03-27 1997-03-27 Cytochrome p450 transducing retroviral vectors

Publications (1)

Publication Number Publication Date
ATE309383T1 true ATE309383T1 (de) 2005-11-15

Family

ID=8092560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919307T ATE309383T1 (de) 1996-03-27 1997-03-27 Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe

Country Status (19)

Country Link
US (1) US6893634B1 (de)
EP (1) EP0892852B1 (de)
JP (1) JP4229982B2 (de)
AT (1) ATE309383T1 (de)
AU (1) AU713382B2 (de)
CA (1) CA2250173A1 (de)
CZ (1) CZ288074B6 (de)
DE (1) DE69730595D1 (de)
DK (1) DK0892852T3 (de)
ES (1) ES2253775T3 (de)
HU (1) HU221349B1 (de)
IL (1) IL125795A0 (de)
NO (1) NO325392B1 (de)
NZ (1) NZ331765A (de)
PL (1) PL188323B1 (de)
RU (2) RU2223788C2 (de)
SI (1) SI0892852T1 (de)
SK (1) SK282744B6 (de)
WO (1) WO1997035994A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4119952B2 (ja) 1995-06-27 2008-07-16 バヴァリアン・ノルディック・アクティーゼルスカブ ウイルス粒子産生カプセル化細胞
CZ288074B6 (cs) 1996-03-27 2001-04-11 Bavarian Nordic Research Institute A/S Kapsule zapouzdřující buňky produkující cytochrom P450
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
WO2000017366A2 (en) * 1998-09-21 2000-03-30 Transgene S.A. Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
JP2002534397A (ja) * 1999-01-04 2002-10-15 エムエル ラボラトリーズ ピーエルシー 癌の処置のためのｐ４５０／アセトアミノフェンｇｄｅｐｔ
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
JP2005503162A (ja) * 2001-09-21 2005-02-03 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクター
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
MX2015006813A (es) * 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335798C (en) 1988-05-17 1995-06-06 Sloan Kettering Institute For Cancer Research Retroviral vector
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
EE03492B1 (et) 1994-09-02 2001-08-15 GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH Mitte-autoinaktiveeruvad ekspressiooni suunavad retroviiruslikud vektorid
JP4119952B2 (ja) 1995-06-27 2008-07-16 バヴァリアン・ノルディック・アクティーゼルスカブ ウイルス粒子産生カプセル化細胞
JPH11511979A (ja) * 1995-09-06 1999-10-19 ババリアン・ノルディック・リサーチ・インスティテュート・アクティーゼルスカブ ヒト乳癌細胞を含むヒト乳腺細胞を標的として、連結された異種性遺伝子を発現させるためのｗａｐまたはｍｍｔｖ制御配列の使用
CZ288074B6 (cs) 1996-03-27 2001-04-11 Bavarian Nordic Research Institute A/S Kapsule zapouzdřující buňky produkující cytochrom P450

Also Published As

Publication number Publication date
CZ288074B6 (cs) 2001-04-11
SK132398A3 (en) 1999-04-13
WO1997035994A2 (en) 1997-10-02
US6893634B1 (en) 2005-05-17
DK0892852T3 (da) 2006-03-06
AU2382797A (en) 1997-10-17
NO325392B1 (no) 2008-04-21
DE69730595D1 (de) 2004-10-14
HUP9904116A3 (en) 2001-01-29
AU713382B2 (en) 1999-12-02
SI0892852T1 (sl) 2006-04-30
CZ305098A3 (cs) 1999-01-13
WO1997035994A3 (en) 1997-11-20
SK282744B6 (sk) 2002-12-03
NZ331765A (en) 2000-02-28
JP4229982B2 (ja) 2009-02-25
RU2223788C2 (ru) 2004-02-20
EP0892852A2 (de) 1999-01-27
NO984540D0 (no) 1998-09-28
PL188323B1 (pl) 2005-01-31
NO984540L (no) 1998-09-28
CA2250173A1 (en) 1997-10-02
IL125795A0 (en) 1999-04-11
JP2000509249A (ja) 2000-07-25
RU2185821C2 (ru) 2002-07-27
EP0892852B1 (de) 2005-11-09
HUP9904116A2 (hu) 2000-04-28
ES2253775T3 (es) 2006-06-01
PL329071A1 (en) 1999-03-15
HU221349B1 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
ATE309383T1 (de) Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe
IL156399A (en) Use of Changed Erythropoietin to Beat Drugs to Protect, Rehabilitate and Amplify Cells, Tissues and Organs Responding to Erythropoietin
BR0113235A (pt) Composições e métodos para a terapia e a diagnose de malignidades associadas com her-2/neu
DE69600065D1 (de) Dermatologische und/oder pharmazeutische Zubereitung, ihre Herstellung und Anwendung
PT974365E (pt) Utilizacao de um polimero do tipo acrilico como agente de desagregacao, processo para fabricar comprimidos e comprimidos resultantes do mesmo
PL352985A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
PT934058E (pt) Forma estavel de medicamento para a administracao por via oral com derivados de benzimidazole como substancia activa e processo para a sua producao
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
ATE308331T1 (de) Kombinationspräparat enthaltend monozyten- abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen
PT806952E (pt) Antagonistas da progesterona para a preparacao de medicamentos para o tratamento de hemorragias uterinas disfuncionais
WO2003054130A3 (de) Polymere duftkapseln und ihre herstellung
FR2623714B1 (fr) Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
DE3682811D1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
DE3280173D1 (de) Superoxid-dismutase, ihre herstellung und dieselbe enthaltende pharmazeutische zusammensetzungen.
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ATE354342T1 (de) Kosmetische oder medizinische zubereitung für die topische anwendung
DE69925307D1 (de) Verwendung von unverseifbaren pflanzlichen ölen für die herstellung pharmazeutischer präparate
BR0115336A (pt) Método para fabricar um produto fibroso celulósico, produto fibroso celulósico ligado, e, produto absorvente de cuidado pessoal
DE69905714T2 (de) Platinkomplex, dessen herstellung und dessen therapeutische anwendung
DE68905171T2 (de) Benzol-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die diese enthalten.
ES2161913T3 (es) Complejos cationicos trinucleares de platino que tienen una actividad antitumoral y composiciones farmaceuticas que los contienen.
DE69815854D1 (de) Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln
DE59813469D1 (de) Linker-nucleosid, seine herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
UEP Publication of translation of european patent specification

Ref document number: 0892852

Country of ref document: EP

REN Ceased due to non-payment of the annual fee